The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[FABP1 protein affects the transport of Dronabinol] which affects the abundance of 11-hydroxy-delta(9)-tetrahydrocannabinol 11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [11-(dansylamino)undecanoic acid binds to FABP1 protein] 11-hydroxy-delta(9)-tetrahydrocannabinol affects the folding of and results in increased stability of FABP1 protein; 11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]
glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA]
[[APOE protein affects the susceptibility to [Cholesterol, Dietary co-treated with Dietary Fats]] which affects the susceptibility to JZL 184] which affects the abundance of glyceryl 2-arachidonate
glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]]
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]
glyceryl 2-arachidonate results in increased expression of ATF4 mRNA iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA]
CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid
CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid
[CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of glyceryl 2-arachidonate; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate results in increased expression of CNR1 mRNA [GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein]
[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate binds to and results in increased activity of CNR2 protein; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate
glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]
glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]
glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]
1-((fluoro(methyl)phosphoryl)oxy)-3-isopropoxypropan-2-yl oleate inhibits the reaction [DAGLA protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate]
glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein]
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]
FABP1 protein affects the abundance of glyceryl 2-arachidonate FABP1 protein affects the reaction [Dronabinol results in increased abundance of glyceryl 2-arachidonate]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide]
FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]]
HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea inhibits the reaction [HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate]
glyceryl 2-arachidonate results in decreased expression of IL1B mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]]
glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]]
glyceryl 2-arachidonate results in decreased expression of IL6 mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]]
glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]]
INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]
[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate] MGLL protein affects the abundance of glyceryl 2-arachidonate MGLL protein results in increased degradation of glyceryl 2-arachidonate [FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; [MJN110 results in decreased activity of MGLL protein] which results in decreased hydrolysis of and results in increased abundance of glyceryl 2-arachidonate MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate
glyceryl 2-arachidonate affects the localization of PPARA protein [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]
glyceryl 2-arachidonate metabolite binds to PPARG protein glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA]
PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate 2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate]
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]
glyceryl 2-arachidonate results in decreased expression of TNF mRNA glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein] glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein
anandamide results in decreased susceptibility to APP protein APP protein results in decreased metabolism of anandamide APP protein results in decreased abundance of anandamide
anandamide results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein]
anandamide affects the activity of CNR1 protein CNR1 protein results in increased susceptibility to anandamide anandamide results in decreased expression of CNR1 protein anandamide binds to CNR1 protein anandamide results in increased activity of CNR1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1] [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of anandamide; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]
anandamide affects the activity of CNR2 protein anandamide binds to CNR2 protein anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]
anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] anandamide results in decreased phosphorylation of CREB1 protein
cannabichromene inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; cannabigerol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; delta-8-tetrahydrocannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Dronabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]
anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]
anandamide results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein]
FAAH results in increased degradation of anandamide FAAH gene mutant form results in increased susceptibility to anandamide FAAH gene mutant form results in decreased metabolism of anandamide FAAH protein results in increased degradation of anandamide [Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; FAAH protein results in increased metabolism of and results in decreased activity of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide]; Silybin inhibits the reaction [FAAH protein results in increased metabolism of and results in decreased activity of anandamide] anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; Rimonabant inhibits the reaction [FAAH gene mutant form results in increased susceptibility to anandamide]
11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein] FABP1 protein affects the abundance of anandamide FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide]
anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein] anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]
[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]
anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]
LEP protein results in decreased abundance of anandamide Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide] LEP protein results in decreased activity of anandamide LEP protein results in decreased transport of anandamide
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]
anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] anandamide results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] anandamide results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein PTGS2 results in increased metabolism of anandamide [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]
anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein] anandamide results in increased expression of SELP protein
anandamide results in increased expression of TIMP1 mRNA N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA]
anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein] TNF protein results in increased abundance of anandamide anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein] TRPV1 protein results in increased susceptibility to anandamide anandamide results in increased activity of TRPV1 protein 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein] anandamide binds to TRPV1 protein
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]
[Streptozocin co-treated with arachidonyl-2-chloroethylamide] results in increased expression of BCL2 protein arachidonyl-2-chloroethylamide results in increased expression of BCL2 protein
arachidonyl-2-chloroethylamide results in decreased expression of CARTPT mRNA [arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA
arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]
arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]
CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA] arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA; arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein
arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]
arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA; arachidonyl-2-chloroethylamide results in increased expression of ESRRG protein ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]
arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA]
arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein] ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA] arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA; arachidonyl-2-chloroethylamide results in increased expression of FGF21 protein
arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA]
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA] arachidonyl-2-chloroethylamide results in decreased phosphorylation of FOXO1 protein
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]
arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]
[arachidonyl-2-chloroethylamide co-treated with Glucose] results in increased secretion of INS1 protein; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein] arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein] arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
Acetylcysteine inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; SB 203580 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein]
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]
arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA] arachidonyl-2-chloroethylamide results in increased expression of PMCH mRNA
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA] arachidonyl-2-chloroethylamide results in decreased expression of POMC mRNA
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]
arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA]
arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA; arachidonyl-2-chloroethylamide results in increased expression of TNF protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]
AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]
AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]
Cannabidiol inhibits the reaction [Ethanol results in increased expression of ACACA mRNA]; Cannabidiol inhibits the reaction [Ethanol results in increased expression of ACACA protein]
Cannabidiol results in increased expression of AICDA mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of AICDA mRNA
Cannabidiol results in decreased phosphorylation of AKT1 protein Cannabidiol results in increased phosphorylation of AKT1 protein Cannabidiol results in increased expression of AKT1 mRNA Cannabidiol results in decreased expression of AKT1 mRNA Cannabidiol affects the expression of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cannabidiol results in decreased phosphorylation of AKT1 protein]; [Cannabidiol co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of AKT1 protein; [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of AKT1 mRNA; Acetylcysteine inhibits the reaction [Cannabidiol results in decreased phosphorylation of AKT1 protein]; AM 251 inhibits the reaction [Cannabidiol results in increased phosphorylation of AKT1 protein]; Cannabidiol promotes the reaction [SB 203580 results in decreased phosphorylation of AKT1 protein]; Cannabidiol results in decreased phosphorylation of and results in decreased expression of AKT1 protein modified form; Chloroquine affects the reaction [Cannabidiol results in decreased phosphorylation of AKT1 protein]; LAIR1 protein affects the reaction [Cannabidiol results in decreased phosphorylation of AKT1 protein]; tanespimycin affects the reaction [Cannabidiol affects the expression of AKT1 protein]; VER 155008 affects the reaction [Cannabidiol affects the expression of AKT1 protein]
[Cannabidiol co-treated with moringin] results in decreased expression of APAF1 mRNA Cannabidiol results in decreased expression of APAF1 mRNA Cannabidiol results in increased expression of APAF1 protein
Cannabidiol inhibits the reaction [APP alternative form results in increased expression of IL6 mRNA] [Cannabidiol co-treated with moringin] results in decreased expression of APP mRNA; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GABRA1 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GRIA2 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of SNAP25 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of DLG4 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [APP gene mutant form co-treated with PSEN1 gene mutant form]
[Cannabidiol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] Cannabidiol results in increased expression of AQP3 mRNA; Cannabidiol results in increased expression of AQP3 protein
Cannabidiol results in increased expression of AQP9 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of AQP9 mRNA
Cannabidiol results in increased expression of ATF3 mRNA [Dronabinol co-treated with Cannabidiol] results in increased expression of ATF3 mRNA Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of ATF3 mRNA]
Cannabidiol results in increased expression of BACH1 mRNA Cannabidiol results in decreased expression of BACH1 protein BACH1 protein affects the reaction [Cannabidiol results in increased expression of HMOX1 mRNA]; BACH1 protein affects the reaction [Cannabidiol results in increased expression of HMOX1 protein]; leptomycin B inhibits the reaction [Cannabidiol results in decreased expression of BACH1 protein] [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of BACH1 mRNA
Cannabidiol results in increased expression of BAD protein Cannabidiol results in decreased expression of BAD mRNA [Cannabidiol co-treated with moringin] results in decreased expression of BAD mRNA
Cannabidiol results in increased expression of BAX mRNA; Cannabidiol results in increased expression of BAX protein Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of BAX mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of BAX protein] [Cannabidiol co-treated with moringin] results in decreased expression of BAX mRNA; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of BAX mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of BAX protein]; iodopravadoline inhibits the reaction [Cannabidiol results in decreased expression of BAX protein]; Rimonabant inhibits the reaction [Cannabidiol results in decreased expression of BAX protein]
Cannabidiol inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of BCL2 mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of BCL2 protein] Cannabidiol results in increased expression of BCL2 protein Cannabidiol results in decreased expression of BCL2 mRNA; Cannabidiol results in decreased expression of BCL2 protein
Cannabidiol results in increased expression of BCL2L1 mRNA Cannabidiol results in decreased expression of BCL2L1 mRNA [Cannabidiol co-treated with moringin] results in increased expression of BCL2L1 mRNA; [Cannabidiol results in increased expression of MIR1972-2 mRNA] which results in decreased expression of BCL2L1 mRNA
Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of BECN1 mRNA] [PSEN1 protein affects the susceptibility to Cannabidiol] which results in increased expression of BECN1 protein; Chloroquine inhibits the reaction [Cannabidiol results in increased expression of BECN1 protein] Cannabidiol results in increased expression of BECN1 mRNA; Cannabidiol results in increased expression of BECN1 protein
[Cannabidiol co-treated with moringin] results in decreased expression of BRAF mRNA; [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of BRAF mRNA
Cannabidiol results in decreased expression of BRCA1 mRNA [Cannabidiol co-treated with moringin] results in increased expression of BRCA1 mRNA Cannabidiol results in increased expression of BRCA1 mRNA
[Oxygen co-treated with Ozone] inhibits the reaction [Cannabidiol results in decreased expression of BRCA2 mRNA]; Cannabidiol inhibits the reaction [[Oxygen co-treated with Ozone] results in increased expression of BRCA2 mRNA]
Cannabidiol results in decreased expression of BSG mRNA [Dronabinol co-treated with Cannabidiol] results in decreased expression of BSG mRNA; Cannabidiol promotes the reaction [Dronabinol results in decreased expression of BSG mRNA]; carfilzomib promotes the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of BSG mRNA]; Dronabinol promotes the reaction [Cannabidiol results in decreased expression of BSG mRNA]
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of BTLA mRNA] Cannabidiol results in increased expression of BTLA mRNA
2-chloro-5-nitrobenzanilide inhibits the reaction [Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP1 protein]]; AM 251 inhibits the reaction [Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]]; Cannabidiol binds to and results in decreased activity of CASP1 protein; Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP1 mRNA]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP1 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein]; iodopravadoline inhibits the reaction [Cannabidiol results in decreased expression of CASP1 protein]; Rimonabant inhibits the reaction [Cannabidiol results in decreased expression of CASP1 protein] Cannabidiol results in decreased expression of CASP1 mRNA; Cannabidiol results in decreased expression of CASP1 protein
[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein; [Cannabidiol co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; [Cannabidiol results in decreased expression of MIRLET7A1 mRNA] which results in increased expression of CASP3 mRNA; [Cannabidiol results in decreased expression of MIRLET7A1 mRNA] which results in increased expression of CASP3 protein; Acetylcysteine inhibits the reaction [Cannabidiol results in increased cleavage of CASP3 protein]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased cleavage of CASP3 mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of CASP3 mRNA]; Chloroquine inhibits the reaction [Cannabidiol results in increased cleavage of CASP3 protein]; DIABLO protein affects the reaction [Cannabidiol results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [Cannabidiol results in increased cleavage of CASP3 protein] Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased cleavage of CASP3 protein]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of CASP3 mRNA] Cannabidiol results in increased expression of CASP3 mRNA Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 mRNA]
Cannabidiol results in increased cleavage of CASP7 protein [Cannabidiol co-treated with moringin] results in decreased expression of CASP7 mRNA Cannabidiol results in increased expression of CASP7 mRNA; Cannabidiol results in increased expression of CASP7 protein
Cannabidiol results in decreased expression of CASP8 mRNA [Cannabidiol co-treated with moringin] results in decreased expression of CASP8 mRNA Cannabidiol results in increased cleavage of CASP8 protein
Cannabidiol results in increased expression of CASP9 mRNA Cannabidiol results in increased activity of CASP9 protein Cannabidiol results in increased cleavage of CASP9 protein 3-methyladenine inhibits the reaction [Cannabidiol results in increased activity of CASP9 protein]; [Cannabidiol co-treated with moringin] results in decreased expression of CASP9 mRNA; Chloroquine inhibits the reaction [Cannabidiol results in increased cleavage of CASP9 protein]
Cannabidiol results in decreased activity of CAT protein Cannabidiol results in increased expression of CAT protein Cannabidiol inhibits the reaction [Haloperidol results in decreased activity of CAT protein]
Cannabidiol analog inhibits the reaction [Bleomycin results in decreased expression of CBX8 mRNA] Cannabidiol results in increased expression of CBX8 mRNA
Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL1 mRNA] [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CCL1 mRNA
Cannabidiol results in decreased expression of CCL2 mRNA [Cannabidiol co-treated with Pam(3)CSK(4) peptide] results in increased secretion of CCL2 protein; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Cannabidiol promotes the reaction [FSL-1 lipoprotein, synthetic results in increased secretion of CCL2 protein] Cannabidiol analog inhibits the reaction [Bleomycin results in increased expression of CCL2 mRNA]; Cannabidiol inhibits the reaction [Ethanol results in increased expression of CCL2 mRNA]; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CCL2 mRNA]
Cannabidiol results in increased expression of CCL20 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL20 mRNA]
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CCL22 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL22 mRNA]
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of CCNA2 mRNA Cannabidiol results in decreased expression of CCNA2 mRNA
Cannabidiol promotes the reaction [[Oxygen co-treated with Ozone] results in decreased expression of CCNB1 mRNA] Cannabidiol results in decreased expression of CCNB1 mRNA
Cannabidiol results in decreased expression of CCND1 mRNA; Cannabidiol results in decreased expression of CCND1 protein [Cannabidiol co-treated with moringin] results in increased expression of CCND1 mRNA; Cannabidiol promotes the reaction [[Oxygen co-treated with Ozone] results in decreased expression of CCND1 mRNA] [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CCND1 mRNA
Cannabidiol results in decreased expression of CCNE1 mRNA [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of CCNE1 mRNA Cannabidiol results in decreased expression of CCNE1 mRNA; Cannabidiol results in decreased expression of CCNE1 protein
Cannabidiol results in decreased expression of CCNE2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CCNE2 mRNA
Cannabidiol results in decreased expression of CDC25A mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CDC25A mRNA
[Cannabidiol co-treated with Dronabinol] results in increased expression of CDH1 protein; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CDH1 mRNA]
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA]
Cannabidiol affects the expression of CDK1 protein Cannabidiol results in decreased expression of CDK1 mRNA [Cannabidiol co-treated with moringin] results in increased expression of CDK1 mRNA; tanespimycin affects the reaction [Cannabidiol affects the expression of CDK1 protein]; VER 155008 affects the reaction [Cannabidiol affects the expression of CDK1 protein]
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of CDK2 mRNA Cannabidiol results in decreased expression of CDK2 protein Cannabidiol results in decreased expression of CDK2 mRNA; Cannabidiol results in decreased expression of CDK2 protein
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of CDK4 mRNA Cannabidiol results in decreased expression of CDK4 protein
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CDK5R1 mRNA] Cannabidiol results in decreased expression of CDK5R1 mRNA
Cannabidiol results in increased expression of CDKN1A mRNA Cannabidiol results in decreased expression of CDKN1A mRNA [Cannabidiol co-treated with moringin] results in decreased expression of CDKN1A mRNA Cannabidiol results in increased expression of CDKN1A mRNA; Cannabidiol results in increased expression of CDKN1A protein [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of CDKN1A mRNA
Cannabidiol results in increased expression of CDKN2A mRNA Cannabidiol results in increased expression of CDKN2A mRNA; Cannabidiol results in increased expression of CDKN2A protein Cannabidiol promotes the reaction [[Oxygen co-treated with Ozone] results in increased expression of CDKN2A mRNA] Cannabidiol results in decreased expression of CDKN2A mRNA
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of CEBPB mRNA Cannabidiol results in increased expression of CEBPB mRNA
Cannabidiol results in increased expression of CFLAR mRNA [Cannabidiol co-treated with moringin] results in decreased expression of CFLAR mRNA; [PSEN1 protein affects the susceptibility to Cannabidiol] which affects the expression of CFLAR mRNA
Cannabidiol results in decreased expression of CHRNA2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of CHRNA2 mRNA
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CMPK2 mRNA] 2-chloro-5-nitrobenzanilide inhibits the reaction [Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CMPK2 protein]]; Cannabidiol inhibits the reaction [Lipopolysaccharides promotes the reaction [PPARG protein binds to CMPK2 promoter]]; Cannabidiol inhibits the reaction [Lipopolysaccharides promotes the reaction [PPARG protein results in increased expression of CMPK2 mRNA]]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CMPK2 protein] Cannabidiol results in decreased expression of CMPK2 mRNA; Cannabidiol results in decreased expression of CMPK2 protein
AM 251 inhibits the reaction [Cannabidiol results in increased expression of CNR1 protein]; Cannabidiol analog binds to and results in decreased activity of CNR1 protein; Cannabidiol analog inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR1 protein]; CNR1 polymorphism affects the susceptibility to [Dronabinol co-treated with Cannabidiol]; CNR1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein] Cannabidiol results in decreased expression of CNR1 protein Cannabidiol inhibits the reaction [Methylazoxymethanol Acetate results in decreased methylation of CNR1 promoter]; Cannabidiol inhibits the reaction [Methylazoxymethanol Acetate results in increased expression of CNR1 mRNA]; Cannabidiol inhibits the reaction [Methylazoxymethanol Acetate results in increased expression of CNR1 protein]; Cannabidiol inhibits the reaction [Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein]] [1,3-dimethoxy-5-methyl-2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)benzene co-treated with CNR1 protein] affects the susceptibility to Cannabidiol; Cannabidiol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol co-treated with 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol deficiency] results in increased expression of CNR1 mRNA] CNR1 protein affects the susceptibility to Cannabidiol
Cannabidiol analog binds to and results in increased activity of CNR2 protein; Cannabidiol analog inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR2 protein]; CNR2 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein] Cannabidiol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol co-treated with 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol deficiency] results in decreased expression of CNR2 mRNA] Cannabidiol affects the expression of CNR2 mRNA
Cannabidiol results in increased expression of COL3A1 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of COL3A1 mRNA]
Cannabidiol results in increased expression of COL4A1 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of COL4A1 mRNA]
Cannabidiol results in increased phosphorylation of CREB1 protein Cannabidiol results in decreased expression of CREB1 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Cannabidiol results in increased phosphorylation of CREB1 protein]
Cannabidiol results in decreased phosphorylation of CTNNB1 protein [Cannabidiol co-treated with SB 203580] results in decreased phosphorylation of CTNNB1 protein; Cannabidiol promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of CTNNB1 protein]
Cannabidiol inhibits the reaction [TNF protein results in increased expression of CX3CL1 mRNA] Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of CX3CL1 protein]
Cannabidiol results in increased expression of CXCL1 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL1 mRNA]
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased secretion of CXCL10 protein]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]
Cannabidiol results in increased expression of CXCL2 mRNA [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CXCL2 mRNA; Cannabidiol inhibits the reaction [Ethanol results in increased expression of CXCL2 mRNA] Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL2 mRNA]
Cannabidiol results in increased expression of CXCL1 mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL1 mRNA] [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CXCL1 mRNA
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCL9 mRNA] Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL9 mRNA]
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of CXCR4 mRNA [Dronabinol co-treated with Cannabidiol] results in decreased expression of CXCR4 mRNA; carfilzomib promotes the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of CXCR4 mRNA] Cannabidiol results in increased expression of CXCR4 mRNA
[Cannabidiol co-treated with moringin] results in increased expression of CYCS mRNA; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of CYCS mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of CYCS protein] Cannabidiol results in decreased expression of CYCS mRNA Cannabidiol results in increased expression of CYCS protein
Cannabidiol results in decreased activity of CYP19A1 protein Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]
Cannabidiol results in decreased activity of CYP1A1 protein Cannabidiol results in increased expression of CYP1A1 mRNA AHR protein affects the reaction [Cannabidiol results in increased expression of CYP1A1 mRNA]; herbimycin inhibits the reaction [Cannabidiol results in increased expression of CYP1A1 mRNA]
Cannabidiol results in decreased activity of CYP1A2 protein Cannabidiol results in increased expression of CYP1A2 mRNA [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CYP1A2 mRNA
Cannabidiol results in decreased activity of CYP2B6 protein [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CYP2B10 mRNA Cannabidiol results in increased expression of CYP2B10 mRNA Cannabidiol results in decreased activity of CYP2B10
Cannabidiol results in decreased activity of CYP2C19 protein [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of CYP2C29 mRNA
Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide] CYP2J2 protein results in increased metabolism of Cannabidiol
Cannabidiol results in increased expression of DCT mRNA; Cannabidiol results in increased expression of DCT protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of DCT mRNA]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of DCT mRNA]
Cannabidiol results in increased expression of DDIT3 mRNA Cannabidiol results in increased expression of DDIT3 mRNA; Cannabidiol results in increased expression of DDIT3 protein [Dronabinol co-treated with Cannabidiol] results in increased expression of DDIT3 mRNA; DDIT3 protein affects the reaction [Cannabidiol results in increased cleavage of PARP1 protein]; DDIT3 protein affects the reaction [Cannabidiol results in increased expression of DIABLO protein] [Bilirubin co-treated with Rotenone] promotes the reaction [Cannabidiol results in increased expression of DDIT3 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of DDIT3 mRNA]; Rotenone promotes the reaction [Cannabidiol results in increased expression of DDIT3 mRNA]
Cannabidiol results in increased expression of DDIT4 mRNA [Cannabidiol co-treated with moringin] results in decreased expression of DDIT4 mRNA; [Dronabinol co-treated with Cannabidiol] results in increased expression of DDIT4 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of DDIT4 mRNA
Cannabidiol results in increased expression of DIABLO protein [Cannabidiol co-treated with moringin] results in decreased expression of DIABLO mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cannabidiol promotes the reaction [DIABLO protein binds to XIAP protein]]; Cannabidiol promotes the reaction [DIABLO protein binds to XIAP protein]; DDIT3 protein affects the reaction [Cannabidiol results in increased expression of DIABLO protein]; DIABLO protein affects the reaction [Cannabidiol results in decreased expression of XIAP protein]; DIABLO protein affects the reaction [Cannabidiol results in increased cleavage of CASP3 protein]; DIABLO protein affects the reaction [Cannabidiol results in increased cleavage of PARP1 protein] Cannabidiol affects the localization of DIABLO protein Cannabidiol results in decreased expression of DIABLO mRNA
Cannabidiol affects the methylation of DLG4 gene Cannabidiol inhibits the reaction [amyloid beta-protein (1-42) results in decreased expression of DLG4 protein] [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of DLG4 protein]
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of DLL1 mRNA] Cannabidiol results in increased expression of DLL1 mRNA
Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ATG12 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ATG4B mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of BECN1 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ULK1 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of IL6 protein]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of IL6RA mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of NOS2 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TGFB1 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TNF mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TNF protein]
Cannabidiol results in decreased expression of DRD2 mRNA Cannabidiol inhibits the reaction [Dronabinol results in decreased methylation of DRD2 gene]; Cannabidiol inhibits the reaction [Dronabinol results in increased expression of DRD2 mRNA] Cannabidiol results in decreased methylation of DRD2 gene
[Cannabidiol co-treated with MOG protein modified form] results in increased expression of DUSP6 mRNA; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of DUSP6 mRNA] Cannabidiol results in increased expression of DUSP6 mRNA
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of E2F1 mRNA Cannabidiol results in increased expression of E2F1 mRNA Cannabidiol results in decreased expression of E2F1 mRNA
[Dronabinol co-treated with Cannabidiol] results in decreased expression of EGFR mRNA; [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of EGFR mRNA; Cannabidiol inhibits the reaction [TNF protein results in increased expression of EGFR mRNA]; Pertussis Toxin inhibits the reaction [[Dronabinol co-treated with Cannabidiol] results in decreased expression of EGFR mRNA]
Cannabidiol results in increased expression of EGR1 mRNA Cannabidiol results in decreased expression of EGR1 protein [Dronabinol co-treated with Cannabidiol] results in increased expression of EGR1 mRNA
Cannabidiol results in decreased expression of ELK1 mRNA [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of ELK1 mRNA
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of ERBB2 mRNA; [Oxygen co-treated with Ozone] inhibits the reaction [Cannabidiol results in decreased expression of ERBB2 mRNA]; Cannabidiol inhibits the reaction [[Oxygen co-treated with Ozone] results in decreased expression of ERBB2 mRNA]
Cannabidiol results in increased expression of FAS mRNA [Cannabidiol co-treated with moringin] results in decreased expression of FAS mRNA [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of FAS mRNA
Cannabidiol inhibits the reaction [Ethanol results in increased expression of FASN mRNA]; Cannabidiol inhibits the reaction [Ethanol results in increased expression of FASN protein] Cannabidiol results in decreased expression of FASN mRNA
Cannabidiol results in decreased expression of FGF1 mRNA Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of FGF1 protein]
Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of FGF2 protein] Cannabidiol results in increased expression of FGF2 mRNA
Cannabidiol analog results in increased expression of FGF21 mRNA Cannabidiol analog inhibits the reaction [Bleomycin results in decreased expression of FGF21 protein]; Cannabidiol analog inhibits the reaction [Dietary Fats results in increased expression of FGF21 mRNA]
Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of FGF7 protein] Cannabidiol inhibits the reaction [TNF protein results in increased expression of FGF7 mRNA] Cannabidiol results in increased expression of FGF7 mRNA
Cannabidiol results in increased expression of FLT1 mRNA [Cannabidiol co-treated with Dronabinol] results in increased expression of FLT1 mRNA alternative form
Cannabidiol results in decreased expression of FOS mRNA Cannabidiol results in decreased expression of FOS protein Cannabidiol results in increased expression of FOS mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of FOS mRNA
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GABRA1 protein]
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of GAS1 mRNA Cannabidiol results in decreased expression of GAS1 mRNA Cannabidiol results in increased expression of GAS1 mRNA
[Cannabidiol results in decreased expression of MIRLET7A1 mRNA] which results in increased expression of GAS7 mRNA Cannabidiol results in increased expression of GAS7 mRNA
[Cannabidiol co-treated with moringin] results in increased expression of GRB2 mRNA; [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of GRB2 mRNA
[Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GRIA2 protein]
Cannabidiol results in decreased expression of GSDMD protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased cleavage of GSDMD protein]]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased cleavage of GSDMD protein]
Cannabidiol results in decreased expression of GSK3B mRNA; Cannabidiol results in decreased expression of GSK3B protein; Cannabidiol results in decreased expression of GSK3B protein modified form [Cannabidiol co-treated with moringin] results in increased expression of GSK3B mRNA; capsazepine inhibits the reaction [Cannabidiol results in decreased expression of GSK3B protein modified form]; capsazepine inhibits the reaction [Cannabidiol results in decreased expression of GSK3B protein]
Cannabidiol promotes the reaction [Dronabinol results in increased expression of H2AX protein modified form]; Dronabinol promotes the reaction [Cannabidiol results in increased expression of H2AX protein modified form]
Cannabidiol results in increased expression of HES2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of HES2 mRNA
Cannabidiol results in increased expression of HMOX1 mRNA; Cannabidiol results in increased expression of HMOX1 protein [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of HMOX1 mRNA; [Rotenone co-treated with Bilirubin] inhibits the reaction [Cannabidiol results in increased expression of HMOX1 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of HMOX1 mRNA]; Rotenone promotes the reaction [Cannabidiol results in increased expression of HMOX1 mRNA] HMOX1 protein affects the susceptibility to Cannabidiol [bafilomycin A1 co-treated with tin protoporphyrin IX] promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; [Dronabinol co-treated with Cannabidiol] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [Cannabidiol results in increased expression of HMOX1 protein]; BACH1 protein affects the reaction [Cannabidiol results in increased expression of HMOX1 mRNA]; BACH1 protein affects the reaction [Cannabidiol results in increased expression of HMOX1 protein]; iodopravadoline promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Cannabidiol results in increased expression of HMOX1 protein]; tin protoporphyrin IX promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]
Cannabidiol results in decreased expression of HSPA2 mRNA Cannabidiol results in increased expression of HSPA2 mRNA [Cuprizone co-treated with Cannabidiol] results in decreased expression of HSPA2 protein
[Cannabidiol co-treated with Rotenone] results in increased expression of HSPA5 mRNA; Bilirubin inhibits the reaction [[Cannabidiol co-treated with Rotenone] results in increased expression of HSPA5 mRNA] Cannabidiol results in increased expression of HSPA5 mRNA; Cannabidiol results in increased expression of HSPA5 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA]; AM 251 inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA]; Cannabidiol inhibits the reaction [MLLT11 protein results in decreased expression of ICAM1 protein]; capsazepine inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA]; ICAM1 mutant form inhibits the reaction [Cannabidiol results in increased expression of TIMP1 protein]; iodopravadoline inhibits the reaction [Cannabidiol results in increased expression of ICAM1 mRNA] [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of ICAM1 mRNA Cannabidiol results in increased expression of ICAM1 mRNA; Cannabidiol results in increased expression of ICAM1 protein
Cannabidiol results in decreased expression of ID1 mRNA; Cannabidiol results in decreased expression of ID1 protein ID1 protein affects the susceptibility to Cannabidiol
AM 281 promotes the reaction [Cannabidiol inhibits the reaction [Plant Preparations results in increased activity of IDO1 protein]]; Cannabidiol inhibits the reaction [[Plant Preparations results in increased activity of IDO1 protein] which results in increased abundance of Neopterin]; Cannabidiol inhibits the reaction [Plant Preparations results in increased activity of IDO1 protein]; Cannabidiol inhibits the reaction [Plant Preparations results in increased expression of IDO1 mRNA]; iodopravadoline promotes the reaction [Cannabidiol inhibits the reaction [Plant Preparations results in increased activity of IDO1 protein]]
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IER3 mRNA] Cannabidiol results in increased expression of IER3 mRNA
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of IFNB1 mRNA; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNB1 mRNA]; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IFNB1 protein] [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 protein]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] Cannabidiol results in increased expression of IFNB1 mRNA
[Cannabidiol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [IFNG protein results in increased expression of PSMB8 mRNA]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [IFNG protein results in increased expression of PSMB8 protein]; Cannabidiol affects the reaction [Plant Preparations results in increased secretion of IFNG protein]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]; Cannabidiol inhibits the reaction [IFNG protein results in increased expression of PSMB8 mRNA]; Cannabidiol inhibits the reaction [IFNG protein results in increased expression of PSMB8 protein]; Cannabidiol inhibits the reaction [Plant Preparations results in increased expression of IFNG mRNA]; Cannabidiol promotes the reaction [Dronabinol inhibits the reaction [IFNG protein results in increased expression of PSMB8 mRNA]]; Dronabinol promotes the reaction [Cannabidiol inhibits the reaction [IFNG results in increased expression of PSMB8 mRNA]] Cannabidiol inhibits the reaction [[myelin oligodendrocyte glycoprotein (35-55) results in increased susceptibility to myelin oligodendrocyte glycoprotein (35-55)] which results in increased expression of and results in increased secretion of IFNG protein]
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IFNGR1 mRNA] Cannabidiol results in decreased expression of IFNGR1 mRNA
Cannabidiol results in decreased expression of IGFBP4 mRNA Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IGFBP4 mRNA]
Cannabidiol results in increased expression of IL10 protein Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] [Cannabidiol co-treated with Haloperidol] results in increased expression of IL10 protein; Cannabidiol inhibits the reaction [[myelin oligodendrocyte glycoprotein (35-55) results in increased susceptibility to myelin oligodendrocyte glycoprotein (35-55)] which results in decreased expression of IL10 mRNA]; Cannabidiol promotes the reaction [[myelin oligodendrocyte glycoprotein (35-55) results in increased susceptibility to myelin oligodendrocyte glycoprotein (35-55)] which results in increased expression of and results in increased secretion of IL10 protein]; Cannabidiol promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] Cannabidiol results in decreased expression of IL10 mRNA
Cannabidiol results in decreased expression of IL13RA1 mRNA Cannabidiol analog inhibits the reaction [Bleomycin results in increased expression of IL13RA1 mRNA]
Cannabidiol inhibits the reaction [[myelin oligodendrocyte glycoprotein (35-55) results in increased susceptibility to myelin oligodendrocyte glycoprotein (35-55)] which results in increased expression of and results in increased secretion of IL17A protein]
iodopravadoline inhibits the reaction [Cannabidiol results in decreased expression of IL18 protein]; Rimonabant inhibits the reaction [Cannabidiol results in decreased expression of IL18 protein] Cannabidiol results in decreased expression of IL18 mRNA; Cannabidiol results in decreased expression of IL18 protein
Cannabidiol results in increased expression of IL1A mRNA [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of IL1A mRNA
[Bleomycin co-treated with Cannabidiol analog] results in decreased expression of IL1B mRNA; Cannabidiol inhibits the reaction [Ethanol results in increased expression of IL1B mRNA]; Cannabidiol inhibits the reaction [Haloperidol results in increased expression of IL1B protein]; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA]; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL1B protein]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL1B mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased secretion of IL1B protein] Cannabidiol results in increased expression of IL1B mRNA Cannabidiol results in decreased expression of IL1B mRNA Cannabidiol results in decreased secretion of IL1B protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; [Cannabidiol co-treated with CpG ODN 2395] results in decreased secretion of IL1B protein; Cannabidiol inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased secretion of IL1B protein]; Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B mRNA]; Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B protein]; Cannabidiol inhibits the reaction [Imiquimod results in increased secretion of IL1B protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Cannabidiol inhibits the reaction [Pam(3)CSK(4) peptide results in increased secretion of IL1B protein]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of IL1B mRNA] Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] Cannabidiol results in decreased expression of IL1B mRNA; Cannabidiol results in decreased expression of IL1B protein
Cannabidiol inhibits the reaction [TNF protein results in decreased expression of IL1R1 mRNA] Cannabidiol results in decreased expression of IL1R1 mRNA
Cannabidiol results in increased secretion of IL2 protein Cannabidiol promotes the reaction [Pam(3)CSK(4) peptide results in increased secretion of IL2 protein] [Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of IL2 mRNA
Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased secretion of IL3 protein]
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of IL6 mRNA; [Rotenone co-treated with Bilirubin] inhibits the reaction [Cannabidiol results in increased expression of IL6 mRNA]; Bilirubin inhibits the reaction [Cannabidiol results in increased expression of IL6 mRNA]; Cannabidiol analog inhibits the reaction [Bleomycin results in increased expression of IL6 mRNA]; Cannabidiol inhibits the reaction [APP alternative form results in increased expression of IL6 mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of IL6 protein]; Cannabidiol inhibits the reaction [Haloperidol results in increased expression of IL6 mRNA]; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Rotenone inhibits the reaction [Cannabidiol results in increased expression of IL6 mRNA] Cannabidiol inhibits the reaction [CpG ODN 2395 results in increased secretion of IL6 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; Cannabidiol promotes the reaction [FSL-1 lipoprotein, synthetic results in decreased secretion of IL6 protein]; Cannabidiol promotes the reaction [Imiquimod results in increased secretion of IL6 protein] Cannabidiol results in decreased expression of IL6 mRNA Cannabidiol results in increased expression of IL6 mRNA; Cannabidiol results in increased expression of IL6 protein Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
Cannabidiol results in decreased expression of IL6RA mRNA Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of IL6RA mRNA]
Cannabidiol promotes the reaction [Glucose results in increased secretion of INS1 protein] Cannabidiol results in increased expression of INS1 protein Cannabidiol analog results in increased secretion of INS1 protein
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C affects the localization of IRF3 protein]; Cannabidiol inhibits the reaction [Poly I-C affects the localization of IRF3 protein]
Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of IRF4 mRNA] Cannabidiol results in increased expression of IRF4 mRNA
Cannabidiol inhibits the reaction [ITGB3 protein results in increased expression of ITGAV mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA]
Cannabidiol results in increased expression of ITGB1 mRNA [Cannabidiol co-treated with moringin] results in decreased expression of ITGB1 mRNA; [Cuprizone co-treated with Cannabidiol] results in decreased expression of ITGB1 protein
[Cannabidiol co-treated with moringin] results in decreased expression of JUN mRNA; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of JUN mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [Cannabidiol results in increased phosphorylation of JUN protein]
Cannabidiol results in decreased expression of KRAS mRNA [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of KRAS mRNA
Cannabidiol results in increased expression of LAIR1 protein LAIR1 protein affects the reaction [Cannabidiol results in decreased phosphorylation of AKT1 protein]; LAIR1 protein affects the reaction [Cannabidiol results in decreased phosphorylation of MTOR protein]
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of LPIN1 mRNA Cannabidiol results in increased expression of LPIN1 mRNA
Cannabidiol results in decreased expression of MAFB mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of MAFB mRNA
Cannabidiol affects the methylation of MAP2K1 gene [Cannabidiol co-treated with moringin] results in increased expression of MAP2K1 mRNA; [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of MAP2K1 mRNA; [Oxygen co-treated with Ozone] inhibits the reaction [Cannabidiol results in decreased expression of MAP2K1 mRNA]; Cannabidiol inhibits the reaction [[Oxygen co-treated with Ozone] results in decreased expression of MAP2K1 mRNA]
Cannabidiol results in increased expression of MAP2K2 mRNA [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of MAP2K2 mRNA; [Oxygen co-treated with Ozone] inhibits the reaction [Cannabidiol results in increased expression of MAP2K2 mRNA]; Cannabidiol inhibits the reaction [[Oxygen co-treated with Ozone] results in decreased expression of MAP2K2 mRNA]
Cannabidiol results in increased phosphorylation of MAPK1 protein Cannabidiol affects the phosphorylation of MAPK1 protein Cannabidiol analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK1 protein] Cannabidiol results in decreased expression of MAPK1 mRNA [Cannabidiol co-treated with Dronabinol] results in increased phosphorylation of MAPK1 protein; [Cannabidiol co-treated with moringin] results in increased expression of MAPK1 mRNA; [Chloroquine co-treated with Cannabidiol] affects the phosphorylation of MAPK1 protein; [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of MAPK1 mRNA; Cannabidiol results in decreased phosphorylation of and results in decreased expression of MAPK1 protein modified form; Chloroquine affects the reaction [Cannabidiol affects the phosphorylation of MAPK1 protein]; iodopravadoline inhibits the reaction [Cannabidiol results in increased phosphorylation of MAPK1 protein]; tanespimycin affects the reaction [Cannabidiol affects the expression of MAPK1 protein]; VER 155008 affects the reaction [Cannabidiol affects the expression of MAPK1 protein]
Cannabidiol results in increased phosphorylation of MAPK3 protein Cannabidiol affects the phosphorylation of MAPK3 protein Cannabidiol analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK3 protein] [Cannabidiol co-treated with Dronabinol] results in increased phosphorylation of MAPK3 protein; [Cannabidiol co-treated with moringin] results in increased expression of MAPK3 mRNA; [Chloroquine co-treated with Cannabidiol] affects the phosphorylation of MAPK3 protein; Cannabidiol results in decreased phosphorylation of and results in decreased expression of MAPK3 protein modified form; Chloroquine affects the reaction [Cannabidiol affects the phosphorylation of MAPK3 protein]; iodopravadoline inhibits the reaction [Cannabidiol results in increased phosphorylation of MAPK3 protein]; tanespimycin affects the reaction [Cannabidiol affects the expression of MAPK3 protein]; VER 155008 affects the reaction [Cannabidiol affects the expression of MAPK3 protein]
Cannabidiol results in increased phosphorylation of MAPK8 protein Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of MAPK8 mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of MAPK8 protein]
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MDM2 mRNA Cannabidiol results in increased expression of MDM2 mRNA
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR146 mRNA; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of MIR146 mRNA] Cannabidiol results in decreased expression of MIR146 mRNA
[Cannabidiol co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of MIR34A mRNA Cannabidiol results in increased expression of MIR34A mRNA
Cannabidiol results in increased expression of MIR449A mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of MIR449A mRNA
[Cannabidiol results in decreased expression of MIRLET7A1 mRNA] which results in increased expression of CASP3 mRNA; [Cannabidiol results in decreased expression of MIRLET7A1 mRNA] which results in increased expression of CASP3 protein; [Cannabidiol results in decreased expression of MIRLET7A1 mRNA] which results in increased expression of GAS7 mRNA
Cannabidiol results in increased expression of MITF mRNA; Cannabidiol results in increased expression of MITF protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of MITF mRNA]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of MITF mRNA]
Cannabidiol results in decreased expression of MMP9 mRNA; Cannabidiol results in decreased expression of MMP9 protein [Cannabidiol co-treated with Dronabinol] results in increased expression of MMP9 mRNA; Cannabidiol inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased secretion of MMP9 protein]
[Cannabidiol co-treated with MOG protein modified form] results in increased expression of DUSP6 mRNA; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of ATF3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CDK5R1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CREM mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CSRNP1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCL9 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of CXCR1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of DGAT1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of FDPS mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of GPR83 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IER3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IFNGR1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IGFBP4 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL12A mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL1B mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of IL3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of JAML mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of NR4A3 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of SPHK1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFRSF18 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFRSF9 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFSF11 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TNFSF14 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of TUBB2B mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of VPS37B mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased expression of XCL1 mRNA]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased secretion of IL1B protein]; Cannabidiol inhibits the reaction [MOG protein modified form results in increased secretion of IL3 protein]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of BTLA mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CD69 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of CMPK2 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of DUSP6 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of GBP11 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of GFOD1 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of IRF4 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of MX2 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of PPIC mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of RSAD2 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TAGAP mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TNFSF8 mRNA]; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of TRIM30A mRNA]
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of MR1 mRNA Cannabidiol results in increased expression of MR1 mRNA
[Cannabidiol co-treated with moringin] results in increased expression of MTOR mRNA; Acetylcysteine inhibits the reaction [Cannabidiol results in decreased phosphorylation of MTOR protein]; Cannabidiol results in decreased phosphorylation of and results in decreased expression of MTOR protein modified form; LAIR1 protein affects the reaction [Cannabidiol results in decreased phosphorylation of MTOR protein] Cannabidiol results in decreased expression of MTOR protein Cannabidiol results in increased expression of MTOR mRNA
Cannabidiol results in decreased expression of MYCN mRNA [Cannabidiol results in increased expression of MIR1972-2 mRNA] which results in decreased expression of MYCN mRNA
[Plant Extracts results in increased abundance of Cannabidiol] which results in increased expression of MYD88 mRNA Cannabidiol results in decreased expression of MYD88 mRNA
Cannabidiol results in increased expression of NDRG1 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of NDRG1 mRNA
Cannabidiol results in decreased expression of NFATC2 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of NFATC2 mRNA
Cannabidiol results in increased expression of NFE2L2 mRNA; Cannabidiol results in increased expression of NFE2L2 protein NFE2L2 protein affects the reaction [Cannabidiol results in increased expression of HMOX1 protein]
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of NFKB2 mRNA Cannabidiol results in decreased expression of NFKB2 mRNA
Cannabidiol results in decreased expression of NLRP3 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein]; iodopravadoline inhibits the reaction [Cannabidiol results in decreased expression of NLRP3 protein]; Rimonabant inhibits the reaction [Cannabidiol results in decreased expression of NLRP3 protein] Cannabidiol results in decreased expression of NLRP3 mRNA; Cannabidiol results in decreased expression of NLRP3 protein
Cannabidiol results in increased expression of NOS2 mRNA Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of NOS2 mRNA]; Cannabidiol inhibits the reaction [Haloperidol results in increased expression of NOS2 mRNA] Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of NOS2 protein]
Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of NOX4 mRNA]; Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of NOX4 protein]
Cannabidiol results in increased expression of NUPR1 mRNA NUPR1 protein affects the reaction [Cannabidiol results in decreased expression of XIAP protein] Cannabidiol results in increased expression of NUPR1 mRNA; Cannabidiol results in increased expression of NUPR1 protein
Cannabidiol promotes the reaction [Naloxone inhibits the reaction [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to and results in increased activity of OPRM1 protein]] [Cannabidiol co-treated with Naltrexone] results in decreased expression of OPRM1 mRNA; Cannabidiol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol co-treated with 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol deficiency] results in increased expression of OPRM1 mRNA]
Cannabidiol results in increased cleavage of PARP1 protein [Cannabidiol co-treated with moringin] results in decreased expression of PARP1 mRNA; DDIT3 protein affects the reaction [Cannabidiol results in increased cleavage of PARP1 protein]; DIABLO protein affects the reaction [Cannabidiol results in increased cleavage of PARP1 protein] Cannabidiol results in decreased expression of PARP1 mRNA
[Cannabidiol co-treated with moringin] results in decreased expression of PIK3CB mRNA; [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of PIK3CB mRNA Cannabidiol results in increased expression of PIK3CB mRNA
[Cannabidiol co-treated with moringin] results in decreased expression of PIK3CD mRNA; [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of PIK3CD mRNA Cannabidiol results in decreased expression of PIK3CD mRNA
Cannabidiol results in increased expression of PPARG mRNA Cannabidiol analog results in increased activity of PPARG protein Cannabidiol analog results in increased expression of PPARG mRNA alternative form Cannabidiol analog binds to PPARG protein Cannabidiol results in decreased expression of PPARG protein [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of PPARG mRNA; Cannabidiol analog inhibits the reaction [Rosiglitazone results in increased activity of PPARG protein]; T 0070907 inhibits the reaction [Cannabidiol analog results in increased expression of PPARG mRNA alternative form] Cannabidiol binds to PPARG protein Cannabidiol analog binds to and results in increased activity of PPARG protein; Cannabidiol inhibits the reaction [Lipopolysaccharides promotes the reaction [PPARG protein binds to CMPK2 promoter]]; Cannabidiol inhibits the reaction [Lipopolysaccharides promotes the reaction [PPARG protein results in increased expression of CMPK2 mRNA]]; Cannabidiol results in increased expression of and affects the localization of PPARG protein; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Cannabidiol affects the localization of PPARG protein]
Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GABRA1 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of GRIA2 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of SNAP25 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in increased expression of DLG4 protein]; [Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [APP gene mutant form co-treated with PSEN1 gene mutant form]; [PSEN1 protein affects the susceptibility to Cannabidiol] which affects the expression of ATG4A mRNA; [PSEN1 protein affects the susceptibility to Cannabidiol] which affects the expression of CFLAR mRNA; [PSEN1 protein affects the susceptibility to Cannabidiol] which affects the expression of CTSD mRNA; [PSEN1 protein affects the susceptibility to Cannabidiol] which affects the expression of DEPTOR mRNA; [PSEN1 protein affects the susceptibility to Cannabidiol] which affects the expression of PRKACB mRNA; [PSEN1 protein affects the susceptibility to Cannabidiol] which affects the expression of RAB7B mRNA; [PSEN1 protein affects the susceptibility to Cannabidiol] which results in increased expression of BECN1 protein Cannabidiol results in decreased expression of PSEN1 mRNA
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [IFNG protein results in increased expression of PSMB8 mRNA]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [IFNG protein results in increased expression of PSMB8 protein]; Cannabidiol inhibits the reaction [IFNG protein results in increased expression of PSMB8 mRNA]; Cannabidiol inhibits the reaction [IFNG protein results in increased expression of PSMB8 protein]; Cannabidiol promotes the reaction [Dronabinol inhibits the reaction [IFNG protein results in increased expression of PSMB8 mRNA]]; Dronabinol promotes the reaction [Cannabidiol inhibits the reaction [IFNG results in increased expression of PSMB8 mRNA]]
[Cannabidiol co-treated with moringin] results in decreased expression of PTEN mRNA Cannabidiol results in increased expression of PTEN mRNA; Cannabidiol results in increased expression of PTEN protein
Cannabidiol results in increased expression of PTGS2 mRNA; Cannabidiol results in increased expression of PTGS2 protein [Dronabinol co-treated with Cannabidiol] results in increased expression of PTGS2 mRNA Cannabidiol inhibits the reaction [Hydrogen Peroxide results in increased expression of PTGS2 mRNA]
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of RAC1 mRNA; Cannabidiol inhibits the reaction [TNF protein results in increased expression of RAC1 mRNA]
[Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of RAF1 mRNA Cannabidiol results in decreased expression of RAF1 mRNA
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of RELA mRNA; Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein] Cannabidiol results in decreased expression of RELA mRNA Cannabidiol results in increased localization of RELA protein Cannabidiol results in decreased phosphorylation of RELA protein [Cannabidiol co-treated with 3-(4-methylphenylsulfonyl)-2-propenenitrile] results in decreased phosphorylation of RELA protein; [Cannabidiol co-treated with 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased phosphorylation of RELA protein; [Cannabidiol co-treated with moringin] results in increased expression of RELA mRNA; [Chloroquine co-treated with Cannabidiol] results in decreased phosphorylation of RELA protein; Cannabidiol promotes the reaction [RELA protein binds to RELA promoter]; SN50 peptide inhibits the reaction [Cannabidiol results in increased localization of RELA protein]
Cannabidiol results in increased expression of RELB mRNA [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of RELB mRNA; [Oxygen co-treated with Ozone] inhibits the reaction [Cannabidiol results in increased expression of RELB mRNA]
[Oxygen co-treated with Ozone] promotes the reaction [Cannabidiol results in decreased expression of RHOA mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of RHOA mRNA]; Cannabidiol promotes the reaction [[Oxygen co-treated with Ozone] results in decreased expression of RHOA mRNA]
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of RORA mRNA Cannabidiol results in increased expression of RORA mRNA
Cannabidiol inhibits the reaction [[myelin oligodendrocyte glycoprotein (35-55) results in increased susceptibility to myelin oligodendrocyte glycoprotein (35-55)] which results in increased expression of RORC mRNA]
[lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of RSAD2 mRNA; Cannabidiol promotes the reaction [MOG protein modified form results in increased expression of RSAD2 mRNA] Cannabidiol results in increased expression of RSAD2 mRNA
Cannabidiol inhibits the reaction [Ethanol results in increased expression of SELE mRNA]; Cannabidiol inhibits the reaction [Ethanol results in increased expression of SELE protein]
Cannabidiol results in increased expression of SERPINB2 mRNA Cannabidiol analog inhibits the reaction [Bleomycin results in increased expression of SERPINB2 mRNA]
Cannabidiol results in decreased expression of SERPINE1 mRNA Cannabidiol analog results in increased expression of SERPINE1 protein Cannabidiol analog inhibits the reaction [Bleomycin results in decreased expression of SERPINE1 protein]; Cannabidiol analog promotes the reaction [Dietary Fats results in increased expression of SERPINE1 protein] SERPINE1 protein results in increased susceptibility to Cannabidiol Cannabidiol results in decreased secretion of SERPINE1 protein Cannabidiol inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; CNR1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein]; CNR2 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein]; TRPV1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein]
[Cannabidiol results in increased expression of MIR1972-2 mRNA] which results in decreased expression of SIRT2 mRNA Cannabidiol results in decreased expression of SIRT2 mRNA
Cannabidiol results in increased expression of SLC30A1 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of SLC30A1 mRNA
Cannabidiol results in increased expression of SLC7A11 mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of SLC7A11 mRNA
[Dronabinol co-treated with Cannabidiol] results in decreased susceptibility to [[APP gene mutant form co-treated with PSEN1 gene mutant form] results in decreased expression of SNAP25 protein]
Cannabidiol inhibits the reaction [3-nitropropionic acid results in decreased expression of SOD1 mRNA] Cannabidiol inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of and results in decreased activity of SOD1 protein]
[Cannabidiol co-treated with moringin] results in decreased expression of SOS1 mRNA; [Oxygen co-treated with Ozone co-treated with Cannabidiol] results in decreased expression of SOS1 mRNA
Cannabidiol results in increased expression of SQSTM1 mRNA Cannabidiol results in increased expression of SQSTM1 mRNA; Cannabidiol results in increased expression of SQSTM1 protein Cannabidiol results in decreased expression of SQSTM1 mRNA; Cannabidiol results in decreased expression of SQSTM1 protein [Dronabinol co-treated with Cannabidiol] results in decreased expression of SQSTM1 protein; Camptothecin inhibits the reaction [Cannabidiol results in increased expression of SQSTM1 mRNA]; Dronabinol promotes the reaction [Cannabidiol results in decreased expression of SQSTM1 protein]
Cannabidiol inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and results in increased activity of STAT3 protein] Cannabidiol results in increased phosphorylation of STAT3 protein Cannabidiol results in decreased expression of STAT3 mRNA [Cannabidiol co-treated with Dronabinol] results in increased phosphorylation of STAT3 protein; [Cannabidiol co-treated with moringin] results in decreased expression of STAT3 mRNA; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Cannabidiol results in increased phosphorylation of STAT3 protein]; AM 251 inhibits the reaction [Cannabidiol results in increased phosphorylation of STAT3 protein]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of STAT3 mRNA]
Cannabidiol inhibits the reaction [[myelin oligodendrocyte glycoprotein (35-55) results in increased susceptibility to myelin oligodendrocyte glycoprotein (35-55)] which results in increased expression of TBX21 mRNA]
[Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA]; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Cannabidiol inhibits the reaction [CpG ODN 2395 results in increased secretion of TGFB1 protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased secretion of TGFB1 protein]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of CDH2 mRNA]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA] Cannabidiol results in increased expression of TGFB1 protein [Bleomycin co-treated with Cannabidiol analog] results in decreased expression of TGFB1 mRNA; Cannabidiol analog inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Cannabidiol analog inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA]; Cannabidiol analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK1 protein]; Cannabidiol analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of MAPK3 protein]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TGFB1 mRNA]
[Cannabidiol co-treated with Naltrexone] results in decreased expression of TH mRNA; Cannabidiol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol co-treated with 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol deficiency] results in decreased expression of TH mRNA]
Cannabidiol results in increased expression of TIMP1 mRNA; Cannabidiol results in increased expression of TIMP1 protein [Cannabidiol co-treated with Dronabinol] results in increased expression of TIMP1 mRNA; ICAM1 mutant form inhibits the reaction [Cannabidiol results in increased expression of TIMP1 protein]
Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] Cannabidiol results in increased expression of TNF protein Cannabidiol results in decreased expression of TNF mRNA Cannabidiol results in decreased secretion of TNF protein [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in decreased expression of TNF mRNA; [Plant Extracts results in increased abundance of Cannabidiol] which affects the expression of TNF mRNA; Cannabidiol analog inhibits the reaction [Peptidoglycan results in increased expression of TNF protein]; Cannabidiol analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]; Cannabidiol inhibits the reaction [Croton Oil results in increased expression of TNF protein]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TNF mRNA]; Cannabidiol inhibits the reaction [DMD gene mutant form results in increased expression of TNF protein]; Cannabidiol inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of TNF protein]; Cannabidiol inhibits the reaction [Ethanol results in increased expression of TNF mRNA]; Cannabidiol inhibits the reaction [Ethanol results in increased expression of TNF protein]; Cannabidiol inhibits the reaction [Haloperidol results in increased expression of TNF mRNA]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] [Cannabidiol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; Cannabidiol analog inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]; Cannabidiol inhibits the reaction [enterotoxin B, staphylococcal results in increased secretion of TNF protein]; Cannabidiol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Cannabidiol inhibits the reaction [TNF protein results in decreased expression of AIMP1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in decreased expression of C5 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in decreased expression of CCL26 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in decreased expression of CCR6 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in decreased expression of IL13 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in decreased expression of IL1R1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in decreased expression of IL5 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of BMP2 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL17 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL20 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL22 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CCL7 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CDH1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of COL3A1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of COL4A1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CSF1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CSF2 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CSF3 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CX3CL1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL11 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL2 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL3 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL5 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of CXCL9 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of EGF mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of EGFR mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of FGF7 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of IL17C mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of IL1B mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of IL7 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of ITGA1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of ITGA5 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of LTB mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of MMP7 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of PLAT mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of PLAUR mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of RAC1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of RHOA mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of SERPINE1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of STAT3 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of TNF mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of TNFRSF11B mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased expression of WISP1 mRNA]; Cannabidiol inhibits the reaction [TNF protein results in increased secretion of MMP9 protein]; Cannabidiol promotes the reaction [Imiquimod results in increased secretion of TNF protein]; Cannabidiol promotes the reaction [Pam(3)CSK(4) peptide results in increased secretion of TNF protein]
Cannabidiol results in decreased expression of TNFRSF11B mRNA Cannabidiol inhibits the reaction [TNF protein results in increased expression of TNFRSF11B mRNA]
Cannabidiol results in increased expression of TNNT1 mRNA iodoresiniferatoxin inhibits the reaction [Cannabidiol results in increased expression of TNNT1 mRNA]
Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Dithiothreitol inhibits the reaction [Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]] Cannabidiol metabolite results in decreased activity of TOP2A protein
Cannabidiol metabolite inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate] Cannabidiol metabolite results in decreased activity of TOP2B protein
Cannabidiol results in decreased expression of TP53 mRNA Cannabidiol results in increased expression of TP53 mRNA; Cannabidiol results in increased expression of TP53 protein Cannabidiol results in decreased expression of TP53 mRNA; Cannabidiol results in decreased expression of TP53 protein [Cannabidiol co-treated with moringin] results in decreased expression of TP53 mRNA; [Oxygen co-treated with Ozone] inhibits the reaction [Cannabidiol results in increased expression of TP53 mRNA]; Cannabidiol inhibits the reaction [[Oxygen co-treated with Ozone] results in increased expression of TP53 mRNA]; Cannabidiol results in increased expression of and results in increased phosphorylation of and affects the localization of and results in increased activity of TP53 protein
Cannabidiol binds to and results in increased activity of TRPA1 protein Cannabidiol results in increased expression of TRPA1 mRNA Cannabidiol results in increased activity of TRPA1 protein
[Cannabidiol results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; Cannabidiol inhibits the reaction [[Capsaicin binds to TRPV1 protein] which results in increased uptake of Calcium]; Cannabidiol inhibits the reaction [[resiniferatoxin binds to TRPV1 protein] which results in increased uptake of Calcium]; Cannabidiol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; Cannabidiol inhibits the reaction [Capsaicin binds to TRPV1 protein]; Cannabidiol inhibits the reaction [resiniferatoxin binds to TRPV1 protein]; capsazepine inhibits the reaction [[Cannabidiol results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; capsazepine inhibits the reaction [Cannabidiol results in increased activity of TRPV1 protein]; TRPV1 protein promotes the reaction [Cannabidiol results in decreased secretion of SERPINE1 protein]
Cannabidiol results in increased activity of TRPV2 protein [Cannabidiol results in increased activity of TRPV2 protein] which results in increased uptake of Calcium Cannabidiol analog binds to and results in increased activity of TRPV2 protein; Cannabidiol binds to and results in increased activity of TRPV2 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased activity of TYR protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of TYR mRNA]; Cannabidiol results in increased expression of and results in increased activity of TYR protein; SB 203580 inhibits the reaction [Cannabidiol results in increased activity of TYR protein]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of TYR mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cannabidiol results in increased expression of TYRP1 mRNA]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of TYRP1 mRNA] Cannabidiol results in increased expression of TYRP1 mRNA; Cannabidiol results in increased expression of TYRP1 protein
[Cannabidiol co-treated with moringin] results in increased expression of UBC mRNA Cannabidiol results in increased expression of UBC mRNA Cannabidiol results in decreased expression of UBC mRNA
Cannabidiol analog results in increased expression of UCP1 protein Dietary Fats inhibits the reaction [Cannabidiol analog results in increased expression of UCP1 protein]
Cannabidiol inhibits the reaction [DMD gene mutant form results in decreased expression of ULK1 mRNA] [Cannabidiol co-treated with moringin] results in decreased expression of ULK1 mRNA
Cannabidiol results in increased expression of VEGFA mRNA [lipopolysaccharide, E coli O55-B5 co-treated with Cannabidiol] results in increased expression of VEGFA mRNA
Cannabidiol affects the methylation of VEGFB gene Cannabidiol analog promotes the reaction [Bleomycin results in increased expression of VEGFB protein]
[Cannabidiol co-treated with Dronabinol] results in decreased expression of VIM protein; [Dronabinol co-treated with Cannabidiol] inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]; Cannabidiol inhibits the reaction [TGFB1 protein results in increased expression of VIM mRNA]
Cannabidiol results in increased expression of VWF mRNA Cannabidiol analog inhibits the reaction [Bleomycin results in decreased expression of VWF protein]
Cannabidiol results in increased ubiquitination of XIAP protein Cannabidiol results in decreased expression of XIAP protein [Cannabidiol co-treated with moringin] results in increased expression of XIAP mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cannabidiol promotes the reaction [DIABLO protein binds to XIAP protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cannabidiol results in decreased expression of XIAP protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cannabidiol results in increased ubiquitination of XIAP protein]; Cannabidiol promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of XIAP protein]; Cannabidiol promotes the reaction [DIABLO protein binds to XIAP protein]; Cannabidiol results in decreased expression of and results in decreased stability of XIAP protein; DIABLO protein affects the reaction [Cannabidiol results in decreased expression of XIAP protein]; NUPR1 protein affects the reaction [Cannabidiol results in decreased expression of XIAP protein]
cannabidiolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA] cannabidiolic acid results in increased expression of CEBPA mRNA
cannabidiolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA] cannabidiolic acid results in increased expression of FABP4 mRNA
cannabidiolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; cannabidiolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; cannabidiolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]
cannabidiolic acid results in increased expression of PPARG mRNA cannabidiolic acid binds to and results in increased activity of PPARG protein; cannabidiolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA] cannabidiolic acid results in decreased expression of PPARG protein
cannabidiolic acid results in decreased expression of PTGS2 mRNA cannabidiolic acid inhibits the reaction [GW 501516 results in increased expression of PTGS2 mRNA]; cannabidiolic acid promotes the reaction [GSK0660 results in decreased expression of PTGS2 mRNA]
cannabidiolic acid results in increased activity of TRPV1 protein [cannabidiolic acid results in increased activity of TRPV1 protein] which results in increased uptake of Calcium
[cannabidiolic acid results in increased activity of TRPV2 protein] which results in increased uptake of Calcium cannabidiolic acid results in increased expression of TRPV2 mRNA
CYP2J2 protein results in increased metabolism of cannabigerol cannabigerol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]
cannabigerol promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA] cannabigerol results in increased expression of FABP4 mRNA
cannabigerol promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; cannabigerol promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]
cannabigerol results in decreased expression of PPARG protein cannabigerol binds to and results in increased activity of PPARG protein; cannabigerol promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA] cannabigerol results in increased expression of PPARG mRNA
cannabigerolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA] cannabigerolic acid results in increased expression of FABP4 mRNA
cannabigerolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FABP4 mRNA]; cannabigerolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]
cannabigerolic acid results in increased expression of PPARG mRNA cannabigerolic acid binds to and results in increased activity of PPARG protein cannabigerolic acid binds to and results in increased activity of PPARG protein; cannabigerolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA] cannabigerolic acid results in decreased expression of PPARG protein
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR1 protein]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; delta(9)-tetrahydrocannabinolic acid promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]]; delta(9)-tetrahydrocannabinolic acid promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]
delta(9)-tetrahydrocannabinolic acid results in increased phosphorylation of MAPK3 protein Rimonabant inhibits the reaction [delta(9)-tetrahydrocannabinolic acid results in increased phosphorylation of MAPK3 protein]
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of NOS2 mRNA]; T 0070907 inhibits the reaction [delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of NOS2 mRNA]]
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Rosiglitazone results in increased expression of PPARG mRNA] delta(9)-tetrahydrocannabinolic acid results in decreased expression of PPARG protein delta(9)-tetrahydrocannabinolic acid results in increased expression of PPARG mRNA
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [TGFB1 protein results in increased expression of TNC mRNA]
delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of TNF mRNA]; T 0070907 inhibits the reaction [delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-nitropropionic acid results in increased expression of TNF mRNA]]
ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]
[HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; HU 308 inhibits the reaction [Glucose results in decreased expression of BECN1 protein]; HU 308 inhibits the reaction [Streptozocin results in decreased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]
3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]
HU 308 inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; HU 308 inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CNR2 mRNA]; HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of CNR2 protein] [HU 308 co-treated with lipopolysaccharide, E. coli O26-B6] results in increased expression of CNR2 mRNA; HU 308 binds to and results in increased activity of CNR2 protein
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL10 protein] HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL10 mRNA]
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL1B mRNA] HU 308 inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; HU 308 inhibits the reaction [IL1B protein results in increased expression of IL6 mRNA]; HU 308 inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; HU 308 inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA] 3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein]; [HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]]; HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL1B protein]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL6 mRNA] HU 308 inhibits the reaction [IL1B protein results in increased expression of IL6 mRNA] HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of IL6 protein]
HU 308 inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; HU 308 inhibits the reaction [TNF protein results in increased expression of MMP1 mRNA]
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased phosphorylation of MTOR protein] HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased phosphorylation of MTOR protein]; HU 308 inhibits the reaction [Glucose results in increased phosphorylation of MTOR protein]
[HU 308 co-treated with Dextran Sulfate] affects the expression of SQSTM1 protein; HU 308 inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]; HU 308 inhibits the reaction [Streptozocin results in increased expression of SQSTM1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]
HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of TGFB1 mRNA] HU 308 promotes the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of TGFB1 protein]
HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of TNF mRNA] HU 308 inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; HU 308 inhibits the reaction [TNF protein results in increased expression of CSF2 mRNA]; HU 308 inhibits the reaction [TNF protein results in increased expression of MMP1 mRNA] HU 308 inhibits the reaction [[Blood Glucose deficiency co-treated with Oxygen deficiency] results in increased expression of TNF protein]
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]
[TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA palmidrol results in decreased expression of CLDN3 mRNA
palmidrol binds to CNR2 protein [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to palmidrol analog
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]
[MK-886 binds to and results in decreased activity of PPARA protein] which results in decreased susceptibility to palmidrol analog; [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] palmidrol affects the localization of PPARA protein
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of ABCA2 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the activity of ABCG2 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL6 protein results in decreased phosphorylation of ACACA protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; JTE 907 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone analog results in decreased expression of ACTA2 protein] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of ACTA2 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased activity of ADAMTS4 protein]; JTE 907 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased activity of ADAMTS4 protein]]; JTE 907 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased activity of ADAMTS4 protein]; JTE 907 promotes the reaction [SDC1 protein inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased activity of ADAMTS4 protein]]]; JTE 907 promotes the reaction [SDC1 protein inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased activity of ADAMTS4 protein]]; SDC1 protein inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased activity of ADAMTS4 protein]]; SDC1 protein inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased activity of ADAMTS4 protein]
ADORA2A protein results in decreased susceptibility to (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of AKT1 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of AKT1 protein; CNR2 protein affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of AKT1 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of APAF1 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [APP alternative form results in increased expression of IL6 mRNA]
AM6545 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of ARG1 mRNA]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of ARHGDIA mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with CNR2 protein] affects the localization of ARRB2 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of BCL2 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of BECN1 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased cleavage of CASP3 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased cleavage of CASP3 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased cleavage of CASP7 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased cleavage of CASP8 protein
AM 281 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased activity of CASP9 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of CCND2 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of CCT7 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of CDK14 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of CITED2 mRNA; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of CITED2 protein
[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR1 protein; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR1 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased activity of MAPK1 protein]; CNR1 affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased activity of CNR1]; Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased activity of CNR1] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to CNR1 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased activity of CNR1; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased activity of CNR1 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR1 protein; 6-methyl-3-(2-nitro-1-(thiophen-2-yl)propyl)-2-phenyl-1H-indole promotes the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to CNR1 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR1 protein] which results in increased expression of FOS protein; CNRIP1 protein inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the localization of CNR1 protein] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR1 protein; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR1 protein] affects the reaction [Potassium Chloride results in increased transport of Calcium]; [Rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; AM 251 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of CNR1 mRNA]; AM 251 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of CNR1 protein]; CNR1 protein affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Potassium Chloride results in increased transport of Calcium]]; Rimonabant inhibits the reaction [[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR1 protein] inhibits the reaction [Potassium Chloride results in increased transport of Calcium]] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of CNR1 mRNA; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of CNR1 protein CNR1 protein mutant form affects the susceptibility to (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone CNR1 protein results in increased susceptibility to (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased degradation of CNR1 protein
CNR2 gene SNP affects the susceptibility to (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR2 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased activity of CNR2 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR2 protein; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to CNR2 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with CNR2 protein] affects the localization of ARRB2 protein; Dronabinol analog inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to CNR2 protein]; GRK2 protein affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]]; ridaifen-B inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR2 protein] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR2 protein; [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; CNR2 protein affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of AKT1 protein]; CNR2 protein affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR2 protein affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of MAPK3 protein]
CNRIP1 protein inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the localization of CNR1 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of CREB1 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of CTSD protein
Acetylcysteine inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of DDIT3 mRNA]; methyl-beta-cyclodextrin inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of DDIT3 mRNA]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of EFS mRNA
RTKI cpd inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of EGFR protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of EIF4B mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of ENO2 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL6 protein results in increased expression of ENO2 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of F3 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased expression of F3 mRNA]
[Acetaminophen co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in decreased expression of FAAH mRNA (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of FAAH mRNA [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Rimonabant] affects the expression of FAAH mRNA
[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR1 protein] which results in increased expression of FOS protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of GCK mRNA; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of GCK protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [amyloid beta-protein (25-35) affects the localization of GJA1 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Cocaine results in increased phosphorylation of GPHN protein]
GPR55 protein affects the susceptibility to (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of GRIA1 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of GRIA2 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]
GRK2 protein affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Cocaine results in decreased expression of HDAC6 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of HSPB3 mRNA
[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Cocaine] results in decreased phosphorylation of HTATSF1 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; [Lipopolysaccharides co-treated with IFNG protein co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in decreased expression of NOS2 mRNA; Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]]; Rimonabant inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in decreased expression of NOS2 mRNA]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL10 protein]; iodopravadoline inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL10 protein]] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL10 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased abundance of N-palmitoylsphingosine]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased activity of ADAMTS4 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of F3 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased expression of F3 mRNA]; JTE 907 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased activity of ADAMTS4 protein]]; JTE 907 promotes the reaction [SDC1 protein inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased activity of ADAMTS4 protein]]]; SDC1 protein inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased activity of ADAMTS4 protein]] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [amyloid beta-protein (25-35) results in increased secretion of IL1B protein] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Carbon Monoxide results in increased expression of IL1B protein]; iodopravadoline inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Carbon Monoxide results in increased expression of IL1B protein]]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL1RL1 protein]; iodopravadoline inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL1RL1 protein]]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL33 protein]; AM 251 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Carbon Monoxide results in increased expression of IL33 protein]]
[Carbon Monoxide co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in increased expression of IL4 protein; iodopravadoline inhibits the reaction [[Carbon Monoxide co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in increased expression of IL4 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [APP alternative form results in increased expression of IL6 mRNA]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL6 protein results in decreased phosphorylation of ACACA protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL6 protein results in decreased phosphorylation of PRKAA1 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL6 protein results in increased expression of ENO2 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL6 protein results in increased expression of TUBB3 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased phosphorylation of and results in decreased activity of KDR protein; fumonisin B1 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased phosphorylation of and results in decreased activity of KDR protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of MAP2 mRNA
CNR1 affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased activity of MAPK1 protein] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Cocaine results in increased expression of MAPK1 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR2 protein affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of MAPK1 protein] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of MAPK1 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased activity of MAPK3 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Cocaine results in increased expression of MAPK3 protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR2 protein affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of and results in increased activity of MAPK3 protein] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of MAPK3 protein CNR1 affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased activity of MAPK3 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of MAPK8 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased phosphorylation of MAPK9 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of MAPT mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of MAT2A mRNA
MGLL protein affects the susceptibility to (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased activity of MMP2 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of MMP2 protein JTE 907 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone analog results in decreased expression of MMP2 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased activity of MMP9 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of MORF4L1 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]
[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Carbon Monoxide] results in increased expression of MRC1 protein; iodopravadoline inhibits the reaction [[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Carbon Monoxide] results in increased expression of MRC1 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of MYC mRNA
[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Rimonabant] affects the expression of NAPEPLD mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of NDRG4 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of NEDD4L mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased localization of NFATC4 protein
[Lipopolysaccharides co-treated with IFNG protein co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in decreased expression of NOS2 mRNA; Rimonabant inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in decreased expression of NOS2 mRNA]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone promotes the reaction [Cocaine results in increased splicing of NPAS2 mRNA]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of NTN1 mRNA
[Acetaminophen co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in decreased expression of NTRK2 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of PACSIN1 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of PARP1 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of PERP mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of PPARA protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of PPP2R1A mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL6 protein results in decreased phosphorylation of PRKAA1 protein]
[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Rimonabant] affects the expression of PTEN mRNA (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of PTEN mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of PTGDS mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of PTPRN mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of RFC1 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of RGS7 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of RIPK1 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of RTN3 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of S1PR3 mRNA
JTE 907 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of SDC1 protein]; JTE 907 promotes the reaction [SDC1 protein inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased activity of ADAMTS4 protein]]]; JTE 907 promotes the reaction [SDC1 protein inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased activity of ADAMTS4 protein]]; SDC1 protein inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL1B protein results in increased activity of ADAMTS4 protein]]; SDC1 protein inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased activity of ADAMTS4 protein] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of SDC1 mRNA; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of SDC1 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of SERPINE2 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of SLC12A5 mRNA; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of SLC12A5 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of SLC1A1 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of SLC1A2 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Isoproterenol results in increased expression of SLC6A1 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of SLC6A3 mRNA; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of SLC6A3 protein AM 251 affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of SLC6A3 mRNA]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of SMN1 mRNA
[Acetaminophen co-treated with (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone] results in decreased expression of SYP mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of TAGLN3 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
AM 251 affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of TH mRNA] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of TH mRNA; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone affects the expression of TH protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Carbon Monoxide results in increased expression of TNF protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]; iodopravadoline inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Carbon Monoxide results in increased expression of TNF protein]] (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [amyloid beta-protein (25-35) results in increased secretion of TNF protein]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of TP53 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of TRAF5 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of TRIB3 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of TRIM8 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of TRPA1 protein; TRPA1 promotes the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased abundance of Calcium] TRPA1 results in increased susceptibility to (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of TRPV1 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased phosphorylation of TRPV1 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of TUBB3 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [IL6 protein results in increased expression of TUBB3 protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of and results in decreased secretion of VEGFA protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of and results in decreased secretion of VEGFA protein; fumonisin B1 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of and results in decreased secretion of VEGFA protein]; Rimonabant inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of and results in decreased secretion of VEGFA protein]; SR 144528 inhibits the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of and results in decreased secretion of VEGFA protein]
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of VPS26C mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of WDR47 mRNA
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in decreased expression of XIAP protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased expression of ZNRF1 mRNA
browse the term
